Research Library

Scientists and members of the public exploring the controversial area of U.S. human embryo and embryoid research will find a complex and sometimes bewildering assortment of federal and state laws. The authors recommend additional guidance, but note slow progress in the development of embryo research policy.

Hospital at Home programs offer an alternative care model for acutely ill patients to receive intensive at-home treatment. With better policy and operations, can this model work at scale in the United States beyond the pandemic?

To understand the variations and impact of national policies, the authors reviewed and analyzed IVF, hESC and human embryo research laws or national guidelines currently in place in the top R&D-investing nations. Regenerative Medicine, Aug. 17, 2020.

For both generic and patented cancer drugs, the free-market economy has not worked well. Solutions are needed to maintain reasonable drug prices that allow for corporate profits and are affordable to patients and to the U.S. health care system.

In a genuine effort to protect patients from adverse events, regulatory burdens and research rigidity in clinical trials have increased to a point at which such protection is outweighing the benefits, and actually harming patients who are unable to be involved in clinical trials.